Proteostasis Therapeutics Inc. sees the early data on its proprietary triple combination of CFTR-modulating drugs in cystic fibrosis as supporting a move into Phase II this year, and Phase III next, but the lung function data in particular pales in comparison to sector-leader Vertex Pharmaceuticals Inc. – a cause for concern for analysts and investors. Proteostasis finished the trading day March 25 down more than two-thirds of its value.
Proteostasis Puts Best Face On Unspectacular CF Combo Data
With data showing a lung function and sweat chloride benefit for its proprietary CFTR-modulating triplet, Proteostasis says it’s moving ahead. But analysts and investors are concerned the effects are less than seen with Vertex drugs.
